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BACKGROUND: The growth factor Angiotensin-2 signals through Angiotensin receptor type 1 (AT1-R) in a broad range of cell types
and tumours and through the type-2 receptor (AT2-R) in a more restricted group of cell types. Although numerous forms of cancer
have been shown to overexpress AT1-R, expression of AT1-R and AT2-R by human renal clear-cell carcinoma (RCCC) is not well
understood. In this study, the expression of both angiotensin receptors was quantified in a retrospective series of RCCC and
correlated with prognostic factors.
METHODS: Angiotensin receptor type 1 and AT2-R expressions were quantified on tumour tissues by immunohistochemistry (IHC),
western blot and quantitative reverse transcriptase PCR (qRT–PCR). IHC results were correlated to Fuhrman’s grade and patient
progression-free survival (PFS).
RESULTS: A total of 84 RCCC were analysed. By IHC, AT1-R and AT2-R were expressed to a greater level in high-grade tumours
(AT1-R: Po0.001, AT2-R: Po0.001). Univariate analysis showed a correlation between PFS and AT1-R or AT2-R expression
(P¼0.001). By multivariate analysis, only AT2-R expression correlated with PFS (HR 1.021, P¼0.006) and cancer stage (Po0.001).
By western blot, AT1-R and AT1-R were also found to be overexpressed in higher Fuhrman’s grade (Po0.01 and P¼0.001
respectively). By qRT–PCR, AT1-R but not AT2-R mRNA were downregulated (P¼0.001 and P¼0.118, respectively).
CONCLUSION: Our results show that AT1-R and AT2-R proteins are overexpressed in the most aggressive forms of RCCC and that
AT2-R expression correlates with PFS. AT1-R or AT2-R blockage could, therefore, offer novel directions for anti-RCCC therapy.
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Renal clear-cell carcinoma (RCCC) accounts for 3% of adult
cancers. Surgical resection is the mainstay of treatment, but about
40% of patients develop distant metastases with poor prognosis.
The renin–angiotensin system (RAS) is well-known for its
regulation of arterial pressure. RAS blockage represents an
important target in the treatment of hypertension (HTA) and
cardiac failure through two pharmacological classes: angiotensin-
converting enzyme inhibitors (ACEi) and angiotensin-receptor
blockers (ARB). The intracellular effects of angiotensin-2 (ATII)
are principally mediated by two receptors: Angiotensin-2 receptor
type 1 (AT1-R) and Angiotensin-2 Receptor type 2 (AT2-R).
Physiologically, both receptors are widely expressed, principally
by heart, vessels, brain and kidney. Both receptors are involved
during renal development (Norwood et al, 1997). In normal
adult kidneys, they localise in the cortex where AT1-R mRNA is
expressed 8–10 fold more than AT2-R mRNA (Matsubara et al,
1998). Angiotensin receptor type 1 is strongly expressed by
mesangial cells (Goldfarb et al, 1994; Arendshorst et al, 1999) and
interlobular endothelial arterial cells (Matsubara et al, 1998;
Arendshorst et al, 1999). In contrast, AT2-R is expressed more
strongly by pre-glomerular endothelial arterial cells and by
interlobular endothelial arterial cells (Goldfarb et al, 1994; Matsubara
et al, 1998; Arendshorst et al, 1999). Both receptors are also
expressed by proximal tubular cells (Weerackody et al, 1997).
Angiotensin-2 receptors regulate many physiological processes.
The main function of ATII is vasoconstriction, as one of the final
steps of RAS (Arendshorst et al, 1999). In many cells, ATII,
through AT1-R facilitates cellular proliferation and angiogenesis
(Stoll et al, 1995; Li et al, 2008), whereas AT2-R has anti-
proliferative properties (Stoll et al, 1995; Nouet and Nahmias,
2000). Moreover in the kidney, ATII induced tubular cell
hypertrophia and proliferation through AT1-R (Chatterjee et al,
1997). In addition, in the kidney, ATII, through AT2-R, triggered
tubular cell proliferation, angiogenesis and apoptosis (Cao et al,
2000). As RCCC cells are developed from tubular renal cells, AT1-R
and AT2-R may also be involved in RCCC development.
Recently, overexpression of AT1-R by in vitro cultured breast-
carcinoma cells (Herr et al, 2008; Rhodes et al, 2009), pancreatic
adenocarcinoma cells (Arafat et al, 2007) or hepatocarcinoma cells Revised 16 July 2010; accepted 3 August 2010
*Correspondence: Dr C Vigneau; E-mail: cecile.vigneau@chu-rennes.fr
6These authors contributed equally to this work
British Journal of Cancer (2010) 103, 1698–1705
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s(Yoshiji et al, 2002) was reported. Overexpression of AT1-R has
also been demonstrated in vivo in different tumours, including:
oestrogen receptor positive breast cancers (Rhodes et al, 2009),
glioblastomas (Juillerat-Jeanneret et al, 2004), ovarian cancers
(Suganuma et al, 2005), squamous cell carcinomas of the skin
(Takeda and Kondo, 2001) and gastric cancers (Rocken et al,
2007). Despite its anti-proliferative effect, AT2-R was also found to
be overexpressed by several cancers such as astrocytomas (Arrieta
et al, 2008) or lung tumours (Tamura et al, 2008) in vivo.
Several clinical series examined the link between AT1-R or
AT2-R overexpression and patient prognosis. Angiotensin receptor
type 1 and AT2-R overexpression was linked to worse prognosis
(Arrieta et al, 2008) in astrocytomas, suggesting a role for these
receptors on carcinogenesis and/or neoangiogenesis.
Little is known about the expression and role(s) of ATII
receptors in RCCC. An initial study described expression in RCCC
by autoradiography but did not correlate this expression
with tumour aggressiveness (Goldfarb et al, 1994). A second
study showed on a mouse model that ARB could prevent the
development of RCCC pulmonary metastasis (Miyajima et al,
2002). The objective of our study was to quantify the expression of
both ATII receptors in RCCC and correlate this expression with
well-known prognostic factors and progression-free survival (PFS).
MATERIALS AND METHODS
This study was designed retrospectively by using the Rennes
database for RCCC from 2002 to 2006 and by exploring expression
of angiotensin-2 receptors by several methods. All patients
undergoing nephrectomy for sporadic RCCC in Rennes are
included in a clinical and histological database, after giving
informed consent.
Tumours specimens
Immediately after macroscopic examination, small samples are
collected from surgical specimens, frozen in liquid nitrogen and
stored at  801C for RNA and protein extraction. Tumour tissues
were also preserved in 10% formalin and embedded in paraffin for
immunostaining. For protein or RNA extractions, 5mm tissue
sections were cut before and after the samples. Hemotoxylin–
eosin staining was performed on sections to confirm or revise the
Fuhrman’s grade and only controlled samples were included.
If necrosis, fibrosis or non-tumourous kidney tissue was above
10% of total tissue examined, the corresponding sample was
excluded from analysis.
Pathological, histological and clinical data
In this study, TNM (Tumour, Node and Metastasis) score, tumour
size and Fuhrman’s grade were extracted from Rennes database for
RCCC. These data are routinely evaluated for each tumour.
Fuhrman’s grade, a nuclear grading system, is based on nuclear
size, shape and prominence of nucleoli. This score is determined in
the most aggressive tumour area and represents one of the key
determinants of RCCC-specific survival (Fuhrman et al, 1982).
Several clinical data were also used such as gender, age, delay
between surgery and progression or death and performance status
at surgical time (ECOG scale (Eastern Cooperative Oncology
Group) (Oken et al, 1982)).
Immunohistochemistry (IHC)
For immunostaining, a representative paraffin block with the
highest Furhman’s grade was selected; 5mm-thick sections were
cut from each block. Immunostaining was performed on formalin-
fixed, paraffin-embedded tissues using the labelled-polymer
method. Slides were dewaxed and rehydrated using xylol and
ethanol, respectively, and transferred in hot citrate buffer
0.01moll
 1 and pH 6 (cooked in 1001C, 40min), left in the
hot buffer for 20 additional minutes and transferred into PBS-T
0.1% buffer for 5min. Endogenous peroxidase was quenched in 3%
hydrogen peroxide for 10min and slides were again transferred
into PBS-Tween 0.1% buffer for 5min. After pre-incubation with
FCS (fetal calf serum) 10% for 20min (for AT1-R), the slides were
incubated with a dilution of 1:500 (in PBS-T 1% FCS) rabbit
polyclonal anti AT1-R antibody (Santa-Cruz, NT, USA; sc-1173)
and a dilution of 1:100 (in primary antibody-diluting buffer) goat
polyclonal anti AT2-R Antibody (Santa-Cruz; K15, sc-48452) at
room temperature for 2h. Control without primary antibody was
always performed at the same time with PBS-T 1% SVF (AT1-R),
and primary antibody-diluting buffer (AT2-R). Sections were
rinsed in PBS-T and incubated with polyclonal rabbit anti-goat
immunoglobulin (1:200 dilution-30min) for AT2-R only, followed
by incubation with HRP (horseradish peroxidase)-labelled poly-
mer conjugated with secondary antibodies (Envision þ Dual link
system-HRP, DAKO). Diaminobenzidine was used as a chromogen
in the presence of hydrogen peroxide. Hematoxylin was used as a
couterstainer. Study specimens were evaluated by a single
uropathologist (NRL) (Microscope: olympus BX51, camera:
olympus DP70). Immunostaining of AT1-R and AT2-R was
expressed as the percentage of AT1-R/AT2-R-positive tumour
cells by scoring at least 1000 cells.
Western blot analysis
Protein lysates were prepared by treating frozen tissues with RIPA
(radio immuno precipitation assay) buffer (consisting of 50mM
Tris-HCL pH8, 150mM NaCl, 0,1% SDS and 1% NP40, 0,5% Na
deoxycholate, 1mM DTT and 10mgml
 1 protease inhibitors) at
41C (30–60min). Tissue lysates were then centrifugated at 13000g
for 30min and supernatants were harvested. Protein concentra-
tions were determined by the Bradford method. A volume of 25mg
of protein (boiled at 951C) were separated by 12.5% SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) and transferred
to a nitrocellulose membrane. Each membrane was blocked with
phosphate buffer saline (PBS) containing 5% skim milk for 2h,
and incubated at 41C overnight with 1:500 of AT1-R (Santa-Cruz;
sc-1173) or 1:200 of AT2-R (Santa-Cruz; H 143, sc-9040). The
membrane was subsequently incubated for 1h at room tempera-
ture with fluorescent-labeled secondary antibody (IRDye Tmn 800-
dilution 1:5000) and analysed using infrared imaging system
(Odyssey-Biosciences). b-Actin was used as loading and blotting
controls and detected by anti-human b-actin (clone AC-15, Sigma,
Lyon, France).
RNA (ribonucleic acid) purification and quantitative
RT–PCR (reverse transcript PCR)
Total RNA was extracted from tissues with the Genelute Mammalian
total RNA Miniprep (RTN-70 Sigma), and treated with DNase I to
avoid genomic DNA contamination. The RNA product was
quantified by absorbance at 260nm. The integrity of RNA samples
was controlled by analysis on bioanalyzer with RNA 6000 Nano assay
Labship (Agilent Technologies, Santa Clara, CA, USA) and ratio
integral number (RIN) was calculated. Only RNA with RIN 48w e r e
further processed and used for cDNA synthesis. A volume of 1mgo f
total RNA was transcribed into cDNA using high capacity cDNA
Archive kit (Applied Biosystems, Foster City, CA, USA).
Quantitative PCR was performed with the PCRq 7900 HT
(Applied biosystems) using power SYBR Green PCR Master mix
(Applied biosystems). The reaction mixture contained 5mlo f
master mix, 0.3ml of each primer (10mM) and 2ml cDNA (diluted
1:40) for a total reaction volume of 10ml. Oligonucleotide primers
were synthesised by Eurogentec (Angers, France). The sequences
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sof these primers were as follows: (forward) 50-ATG-ATT-CCA-
GCG-CCT-GAC-30 and (reverse) 50-GGT-CCA-GAC-GTC-CTG-
TCA-CT-30 for AT1-R, (forward) 50-GGT-TTC-TAG-CAT-ATA-
CAT-CTT-CAA-CCT-30 and (reverse) 50-GCC-CAT-AGA-GGA-
AGA-GTA-GCC-30 for AT2-R, (forward) 50-GGT-CCT-TTC-ACC-
AGC-AAG-CT-30 and (reverse) 50-GCT-TTC-CTT-GGT-CAG-GCA-
GTA-30 for HPRT. The programme was as follows: an initial step at
951C for 10mn and then 40 cycles of 951C for 15s and 601C for
60s. Regression curves were drawn for each sample, and its
relative amount was calculated from the threshold with the
instrument’s software (SDS 2.0) according to the manufacturer’s
instructions. Relative expression levels of the target genes were
normalised mean of an internal control gene, HPRT.
Statistical analysis
Progression-free survival was determined from the date of surgery
to the date of cancer progression or the last follow-up. Non-
parametric tests (Kruskal Wallis) were used to compare means and
proportions. Estimates of the cumulative survival distributions
were calculated according to the Kaplan–Meier method and log-
rank tests were used to compare the differences between groups.
A Cox proportional-hazard regression model was used to test the
independent effects of clinical and pathological variables on
survival. Graphical methods suggested that the proportional-
hazards assumption was reasonable for all selected variables.
A stepwise selection procedure was used to select the final optimal
model. All P-values were two-sided and Po0.05 was considered to
indicate significance. All analyses were conducted with the
Statistical Package for the Social Sciences, version 16.0 (SPSS
Inc., Chicago, IL, USA).
RESULTS
A total of 84 patients who underwent nephrectomy between 2002
and 2006 were included in our study. All protein and RNA extracts
from frozen samples corresponding to IHC Fuhrman’s grade were
selected for western blot and qRT–PCR experiments (n¼55).
Paraffin sections were done on all samples.
In all, 50 men and 34 women were included, with a mean age of
63.7±11.3 years. At the time of surgery, 56 patients were ECOG
0 and 28 ECOG 1; three tumours were Fuhrman’s grade 1 (3.5%),
32 grade 2 (37.6%), 26 grade 3 (30.9%) and 23 grade 4 (27.3%). A
total of 22 patients (26.2%) had metastases at the time of surgery,
as well as 11 (13.1%) had lymph node involvement. Median
tumour size was 7.0±4.10cm. No patient received anti-angiogenic
therapy or chemotherapy before surgery. Mean follow-up was 30
months (±18 months).
For the statistical analysis grade 1 and 2 were combined because
of low number of grade 1 tumours.
Immunohistochemistry
Localisation of AT1-R and AT2-R was described on tumour tissue
and normal surrounding tissue (Figure 1). Angiotensin receptor
type 1 stained all tubular cells, podocytes, epithelial cells of
Bowman’s capsule and vascular smooth-muscle cells in the normal
cortex. AT2-R cortical staining localised only on tubular cells.
Tumour cells, as well as normal renal cells, exhibited cytoplasmic
staining but not membrane or nuclear immunostaining.
A total of 82 tumours were stained for AT1-R (3 Fuhrman’s
grade 1, 31 grade 2, 26 grade 3 and 22 grade 4) and 76 for AT2-R
(3 Fuhrman’s grade 1, 30 Fuhrman’s grade 2, 24 Fuhrman’s grade
3 and 19 Fuhrman’s grade 4). For each sample, the ratio of positive
tumour cells/total tumour cells was expressed as a percentage.
Angiotensin receptor type 1 median ratio was 12.5 % and AT2-R
one was 10%. Figure 2 shows that AT1-R was overexpressed by
Fuhrman’s 4 RCCC compared with other grade tumours (Po0.001;
panel A). Angiotensin type-2 receptor was also overexpressed by
Fuhrman’s 4 RCCC (Po0.001; panel B).
Western blot
Frozen tumours were included in the WB experiments to confirm
IHC results by another semi-quantitative method (Figure 3).
A total of 47 frozen samples (2 Fuhrman’s grade 1, 15 grade 2, 19
grade 3 and 11 grade 4) containing tumour tissue alone were
analysed. Samples with significant proportion of non-tumour
tissue or fibrosis or necrosis (more than 10%) were excluded. The
AT1-R was overexpressed by the higher Fuhrman’s grade tumours
as shown in Figure 3 (Po0.001); panel A). A total of 51 samples
were included to quantify AT2-R by WB (3 Fuhrman’s grade 1, 18
grade 2, 20 grade 3 and 10 grade 4). Angiotensin type-2 receptor
was also significantly increased in high Fuhrman’s grade tumours
(P¼0.001; panel B).
qRT–PCR
By RT–PCR, AT1-R expression was analysed on 55 samples
(3 grade 1 tumours, 17 grade 2, 17 grade 3 and 18 grade 4).
AB CD
EF GH
Figure 1 Staining by IHC on non-tumorous kidney tissue and renal cell carcinoma. Top panel, AT1-R IHC: (A) negative control, (B) staining of non-
tumorous renal tissue, positive on tubular and Bowman’s capsule cells, (C) Fuhrman’s grade 1 renal carcinoma with no staining, (D) Fuhrman’s grade 4 renal
carcinoma with positive staining. Bottom panel, AT2-R IHC: (E) negative control, (F) staining of non-tumorous renal tissue on tubular cells, (G) Fuhrman’s
grade 1 renal carcinoma with no staining, (H) Fuhrman’s grade 4 renal carcinoma with intense staining.  200 magnification for all images.
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sIt was significantly decreased according to the Fuhrman’s grade
(Figure 4 - panel A, Po0.001). However, on the 44 tumours
suitable for analysis (2 grade 1, 12 grade 2, 15 grade 3 and 15 grade
4), AT2-R mRNA was not differentially expressed according to
Fuhrman’s grade (panel B; P¼0.118, NS).
Survival, univariate and multivariate analyses
Progression-free survival was assessed by the Kaplan–Meier
method and compared by log-rank test according to the level of
AT1-R and AT2-R (p or 4median expression determined by IHC
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Figure 3 Quantification by western blot of AT1-R/Actin ratio (A, C) and AT2-R/Actin ratio (B, D). Angiotensin receptor type 1 is over expressed by the
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Figure 2 Angiotensin receptor type 1 (A) and AT2-R (B) expression by IHC according to Fuhrman’s grade. Results are expressed as percentage of
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Figure 4 Reverse transcription–PCR of AT1-R and AT2-R according to Fuhrman’s grade. Angiotensin receptor type 1 expression is significantly
decreased according to the Fuhrman’s grade (panel A, P¼0.001, n¼55). Angiotensin type 2 receptor is not differentially expressed between different
Fuhrman’s grades (panel B; P¼0.118, n¼44).
Angiotensin-2 receptors in renal carcinoma
T Dolley-Hitze et al
1701
British Journal of Cancer (2010) 103(11), 1698–1705 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
smethod). Figure 5 shows that PFS was better when AT1-R was
expressed below 12.5 % (median) by IHC (P¼0.006; panel A) and
AT2-R below 10% (median) (P¼0.001; panel B). Univariate
and multivariate analysis results are presented in Table 1 for
AT1-R and in Table 2 for AT2-R. By univariate analysis, PFS
correlated with AT1-R (P¼0.001), as well as stage (T1/2 vs T3/4,
Po0.001), nodal invasion (Po0.001), distant metastasis (Po0.001),
tumour size (p or 47cm,P¼0.001), Fuhrman’s grade (F1/2 vs F3/4
Po0.001) but not ECOG stage (P¼0.239). By multivariate analysis,
AT1-R did not correlate with PFS (NS) on the contrary to tumour
stage (Po0.001), Fuhrman’s grade (P¼0.044), nodal invasion
(P¼0.003) and ECOG stage (P¼0.005). For AT2-R, univariate
analysis showed that PFS correlated with AT2-R (P¼0.001), as well
as tumour stage (T1/2 vs T3/4, Po0.001), nodal invasion (P¼0.002),
distant metastasis (Po0.001), tumour size (o or 47cm,P¼0.001),
Fuhrman’s grade (F1/2 vs F3/4 Po0.001) but not ECOG stage
(0.253). By multivariate analysis, AT2-R was still correlated with PFS
(P¼0.006) as tumour stage (Po0.001).
DISCUSSION
Our study shows that both AT1-R and AT2-R protein expression
correlate with RCCC aggressiveness and PFS. This relationship
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Table 1 Variables associated with progression-free survival in univariate
analysis and with Cox proportional hazards regression model for AT1-R
expressed by IHC
Variables
(No. of
patients)
Percentage of
progression
P (univariate
analysis)
Multivarate
analysis
hazard ratios
(95% CI) P
Stage
T1/2 (45) 11.1 %
T3/4 (39) 61.5 % o0.001 9.841 o0.001
Nodal invasion
No (73) 28.7 %
Yes (11) 72.7 % o0.001 4.245 0.003
Distant metastasis
No (47) 22.6 %
Yes (37) 68.2 % o0.001 NS
Tumor size 0.001 NS
p7cm (44) 15.9 %
47cm (40) 55 %
Fuhrman’s grade
1+2 (35) 8.5 %
3+4 (49) 53.0 % o0.001 3.688 0.044
AT1Rp or 412.5%
p12.5% (41) 25 %
412.5 % (43) 44.7 % 0.001 NS
ECOG
0 (56) 28.5 %
1 or more (28) 46.4 % 0.239 3.487 0.005
Abbreviations: AT1R¼angiotensin type 1 receptor; CI¼confidence interval;
ECOG¼eastern cooperative oncology group performance status.
Table 2 Variables associated with progression-free survival in univariate
analysis and with Cox proportional hazards regression model for AT2-R
expressed by IHC
Variables
(No. of
patients)
Percentage
of progression
P (univariate
analysis)
Multivarate
analysis
Hazard ratios
(95% CI) P
Stage
T1/2 (45) 11.1 %
T3/4 (39) 61.5 % o0.001 14.297 o0.001
Nodal invasion
No (73) 28.7 %
Yes (11) 72.7 % 0.002 NS
Distant metastasis
No (47) 22.6 %
Yes (37) 68.2 % o0.001 NS
Tumor size 0.001 NS
p7cm (44) 15.9 %
47cm (40) 55 %
Fuhrman’s grade
1+2 (35) 8.5 %
3+4 (49) 53.0 % o0.001 NS
AT2Rp or 410 %
p10% (42) 17.5 %
410% (42) 47.2 % 0.001 1.021 0.006
ECOG
0 (56) 28.5 %
1 or more (28) 46.4 % 0.253 NS
Abbreviations: AT1R¼angiotensin type 1 receptor; CI¼confidence interval;
ECOG¼eastern cooperative oncology group performance status.
Angiotensin-2 receptors in renal carcinoma
T Dolley-Hitze et al
1702
British Journal of Cancer (2010) 103(11), 1698–1705 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssuggests a role for these two receptors in regulating tumour growth
and/or neoangiogenesis and a potential therapeutic effect of
receptor antagonists.
AT1-R overexpression has already been described in other
cancers but not previously for RCCC. This correlation might be
because of a direct effect of ATII on tumour cells. Indeed, ATII
through AT1-R can activate tumour cell proliferation through at
least two simultaneous mechanisms: PI3-kinase/Akt pathway
(Zhao et al, 2010) and EGFR (epithelial growth factor receptor)
trans-activation (Fujiyama et al, 2001; Greco et al, 2003; Uemura
et al, 2003). Secondly, ATII through AT1-R can induce an
increased expression and production in vascular endothelial
growth factor (VEGF) inducing neo-angiogenesis (Arafat et al,
2007; Kosaka et al, 2010). Induction might be triggered by
stabilisation of hypoxia inducible factor-1a (HIF1a), as shown in
prostate cancer model (Richard et al, 2000; Ino et al, 2006; Kosaka
et al, 2010). Positive correlation between AT1-R expression and
VEGF production has been showed in ovarian cancer, in vivo.
Moreover, ATII through AT1-R reduces tumour cell adhesion
although reducing invasion of the basement membrane (Puddefoot
et al, 2006). Lastly, in a mouse model of gastric cancer AT1-R
could trigger lymphangiogenesis (Wang et al, 2008).
AT2-R is overexpressed by some cancers such as gastric cancers
(Rocken et al, 2007) though its role in carcinogenesis remains
controversial. Under physiological conditions, AT2-R has anti-
proliferative properties (Fujiyama et al, 2001), whereas during
carcinogenesis, AT2-R can induce an invasive phenotype, for
example, in gastric cancer (Carl-McGrath et al, 2007), or prevent
cell proliferation (Bose et al, 2009). However, AT2-R has been
shown to counteract the effects of ATII mediated by AT1-R, and
might be upregulated upon prolonged ATII stimulation (Nouet
and Nahmias, 2000). High expression of AT2-R in RCCC could be
either a consequence of AT1-R overexpression or of the high
circulating level of ATII and/or may have specific angiogenesis
effects as in gastric cancer. Even more, in kidney, AT2-R can
physiologically induce tubular cell proliferation during develop-
ment or after kidney injury (Cao et al, 2000). As RCCC develops
from tubular cells, AT2-R overexpression may be one of the
mechanisms by which tubular cell proliferation develops into
carcinogenesis. The strong correlation between tumour aggres-
siveness, PFS and AT2-R expression in our study indeed supports
the hypothesis for a proliferative effect of AT2-R in RCCC, more
than in other type of cancers. Specific in vitro studies, using anti
AT1-R and/or AT2-R inhibitors on RCCC-cultured cells will help
to illuminate the role(s) of AT2-R in renal carcinogenesis.
In our ex vivo study, dissociation between AT1-R and AT2-R
protein expression and RNA synthesis was also observed. As the
staining of both receptors was mainly expressed by tumour cells as
detected by IHC, and because the tumour nature of tissue analysed
was controlled, we suggest that AT1-R and AT2-R mRNA
amplified were indeed synthesised by tumour cells. We also
suggest that post-transcriptional or post-translational mechan-
isms, never described in other type of cancer, might be involved in
RCCC. The underlying mechanisms of receptor synthesis, inter-
nalisation, sequestration and inactivation are incompletely under-
stood (Arendshorst et al, 1999).
The correlation between RAS and RCCC opens new potential
therapeutic strategies in RCCC. Angiotensin-receptor blockers and
ACEi are highly prescribed and well tolerated anti-hypertensive
therapies. Large epidemiological studies suggest potential protec-
tive effects against cancer risk even if results remain controversial
(Lever et al, 1998; Friis et al, 2001). Angiotensin-receptor blockers
and ACEi could act on tumour progression by two different
mechanisms: inhibition of cancer proliferation and/or inhibition of
neovascularization. In experimental studies on different cancer
types, ARB or ACEi showed anti-proliferative effects: in breast
cancer cells (Puddefoot et al, 2006; Rhodes et al, 2009) in human
melanoma xenograft model (de Groot-Besseling et al, 2004),
in murine hepatocellular carcinoma (Noguchi et al, 2003), in
colorectal cancer liver metastases (Neo et al, 2007), on pancreatic
cancer cells (Arafat et al, 2007) or on lung metastases of mouse
RCCC (Miyajima et al, 2002). Inhibition of tumour growth involves
the decreased expression of VEGF. It has been shown for
pancreatic cancer (Arafat et al, 2007; Noguchi et al, 2009) and
for prostate cancer (Kosaka et al, 2010). The inhibition of
endothelial cell tubular formation (Yoshiji et al, 2005) and/or
apoptosis of endothelial or tumour cells (De la Iglesia Inigo et al,
2009) were also described. In a recent model of murine melanoma
graft, ARB-induced tumour growth decrease by low microvascular
density, and the decrease of some angiogenic mediators such as
VEGF-1 and VEGF-2 (Otake et al, 2009). In addition, in animal
models, ARB or ACEi enhance the effect of usual chemotherapies:
in murine hepatocarcinoma in association to interferon- (Noguchi
et al, 2003), in mouse bladder cancer combined with cis-platin by
further suppressing angiogenesis (Kosugi et al, 2009), by enhan-
cing effects of radiation (Ohnuma et al, 2009), or in addition with
K2 vitamin in hepatocellular carcinoma in rats (Yoshiji et al, 2006).
Furthermore, few recent clinical trials reported that ARB could
improve cancer prognosis when used in association with standard
chemotherapies. In a report of three cases of metastatic RCCC,
ARB was associated with cimetidine and cyclo-oxygenase 2
inhibitors allowing prolonged partial remission (Tatokoro et al,
2008). In a retrospective cohort study on advanced non-small-cell
lung cancer, ARB or ACEi were statistically associated with longer
patient survival when used with first-line platinum-based
chemotherapy (Wilop et al, 2009).
One pharmacological AT2-R blocker (PD123319) has been used
with controversial results. It can facilitate tumourogenesis by Pax2
activation and resulted in prostatic cancer-cell proliferation (Bose
et al, 2009). In a gastric cancer model, the same AT2-R blocker
induced cell proliferation and cell viability, but inhibited cell
invasion (Carl-McGrath et al, 2007). In recent work on pancreatic
cancer cells, it also enhanced production of the inflammatory
mediator MCP-1, which promotes tumour invasion (Chehl et al,
2009). According to this tissue specificity of AT2-R expression and
AT2-R blocker effect, overexpression of AT2-R in the RCCC may
suggest a different role of AT2-R and in consequence, different
actions of its blocker.
For RCCC, 40% of the patients develop distant metastases with
poor prognosis. As RCCC are highly vascularises cancers, with
high secretion of VEGF (Rioux-Leclercq et al, 2007), recent
therapies are focused on anti-angiogenic drugs (Rini, 2009): anti-
VEGF antibody (bevacizumab) (Rini et al, 2008) or tyrosine kinase
inhibitors (Sunitinib, sorafenib) (Motzer et al, 2007; Negrier et al,
2009). These drugs already significantly increased patient survival
but PFS is still counted in months (Motzer et al, 2007). Our study
demonstrates that AT1-R and AT2-R are overexpressed in RCCC,
and that this overexpression correlates with tumour aggressiveness
and PFS. In consequence, AT1-R and AT2-R can be used as new
prognosis factors for RCCC but ARB and ACEi can also
be suggested as new adjuvant pathway for RCCC therapy. Indeed,
these results, in addition to already-published experimental and
clinical data on other cancer types, suggest that blocking RAS
might be a way to decrease RCCC growth, neovascularization and
metastasis dissemination. Experimental in vitro and in vivo studies
with ARB and ACEi, in addition to antiangiogenic therapies, are
the following steps to confirm our hypothesis.
CONCLUSION
Our study first report that AT1-R and AT2-R protein expression
can be used as new prognosis factors in RCCC, strongly related to
tumour aggressiveness and worse PFS. These results support the
hypothesis that ARB and ACEi could represent interesting
adjuvant treatments in metastatic RCCC.
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